within Pharmacolibrary.Drugs.ATC.G;

model G03GA30
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.05,
    Cl             = 20 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,
    adminCount     = 1,
    Vd             = 0.0012,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>ATC code G03GA30 refers to estradiol and combinations for systemic use, commonly used in hormone replacement therapy for menopausal symptoms in women. The combinations may include other estrogens or progestogens. These drugs are approved and still in clinical use.</p><h4>Pharmacokinetics</h4><p>Estimated mean pharmacokinetic parameter values for healthy postmenopausal women, oral administration of estradiol valerate as a representative component in combination preparations. No direct PK studies found for the specific fixed-dose combinations with comprehensive compartmental PK model parameters.</p><h4>References</h4><ol><li><p>Battipaglia, C, et al., &amp; Grandi, G (2023). Combined oral contraceptive with estetrol plus drospirenone: from pharmacokinetics to clinical applications. <i>Expert opinion on drug metabolism &amp; toxicology</i> 19(12) 871–879. DOI:<a href=&quot;https://doi.org/10.1080/17425255.2023.2279752&quot;>10.1080/17425255.2023.2279752</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37942662/&quot;>https://pubmed.ncbi.nlm.nih.gov/37942662</a></p></li><li><p>Stanczyk, FZ, et al., &amp; Archer, DF (2024). Comparison of estrogenic components used for hormonal contraception. <i>Contraception</i> 130 110310–None. DOI:<a href=&quot;https://doi.org/10.1016/j.contraception.2023.110310&quot;>10.1016/j.contraception.2023.110310</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37863464/&quot;>https://pubmed.ncbi.nlm.nih.gov/37863464</a></p></li><li><p>Regidor, PA, et al., &amp; Mayr, M (2023). Pharmacological and metabolic effects of drospirenone as a progestin-only pill compared to combined formulations with estrogen. <i>Women&#x27;s health (London, England)</i> 19 17455057221147388–None. DOI:<a href=&quot;https://doi.org/10.1177/17455057221147388&quot;>10.1177/17455057221147388</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36744531/&quot;>https://pubmed.ncbi.nlm.nih.gov/36744531</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end G03GA30;
